CathWorks

Company Overview

Snapshot

Founded in February 2013 by Ifat Lavi and Guy Lavi, CathWorks operates with 51–200 employees. The company raised over $151.79 million across 5 funding rounds from 9 investors. In February 2026, CathWorks was acquired by Medtronic.

Business overview

CathWorks is a medical technology company that develops an advanced computational science platform to optimize coronary artery disease (CAD) therapy decisions. Its core product, the FFRangio System, elevates coronary angiography from visual assessment to an objective, FFR-based decision-making tool for physicians. The system provides quick, precise, and objective intraprocedural FFR guidance, eliminating the need for invasive measurements. CathWorks operates in the Health Tech & Life Sciences sector, specifically within Digital Healthcare and Medical Decision Support, serving healthcare providers with AI-driven solutions.

Strategic signal

In February 2026, CathWorks was acquired by Medtronic for $585 million, with potential milestone payments up to $1 billion. This acquisition, following a strategic partnership initiated in 2022, signifies Medtronic's commitment to integrating innovative AI-driven diagnostic technologies into its interventional cardiology portfolio. The deal validates CathWorks' FFRangio System as a transformative solution for non-invasive coronary artery disease assessment and signals a significant growth opportunity for the technology under a major medical device company.

Company Intelligence Q&A

What was the most significant recent corporate event for CathWorks?

In February 2026, CathWorks was acquired by Medtronic for $585 million, with potential milestone payments that could bring the total deal value to approximately $1 billion.

When did CathWorks enter into a strategic partnership with Medtronic?

In July 2022, Medtronic entered into a strategic partnership with CathWorks, which included an investment and a co-promotion agreement for the FFRangio System, with an option for future acquisition.

What was the outcome of the ALL-RISE Study patient enrollment?

In June 2023, CathWorks announced the enrollment of the first patient in the global ALL-RISE Study, a randomized controlled trial designed to evaluate the clinical and economic benefits of the CathWorks FFRangio System for diagnosing and treating coronary artery disease.

When did CathWorks receive regulatory approval for its FFRangio System in Japan?

In October 2022, CathWorks received regulatory approval in Japan for its fourth-generation CathWorks FFRangio System, allowing for comprehensive physiologic assessment of coronary artery disease without invasive pressure wires.

Who was appointed as CEO of CathWorks in 2021?

In June 2021, CathWorks announced the appointment of Ramin Mousavi as Chief Executive Officer and a member of the Board of Directors.